Jump to section

References

Trials

Economics

Properties

Spectra

Taxonomy

Dabigatran etexilate

Targets (1)Enzymes (6)Transporters (1)Biointeractions (7)

Identification

Accession Number

DB06695

Type

Small Molecule

Groups

Approved

Description

Dabigatran etexilate is an oral prodrug that is metabolized by a serum esterase to dabigatran. It is a synthetic, competitive and reversible direct thrombin inhibitor. Inhibition of thrombin disrupts the coagulation cascade and inhibits the formation of clots. Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients who have undergone total hip or knee replacement surgery, or to prevent stroke and systemic embolism in patients with atrial fibrillation, in whom anticoagulation therapy is indicated. In contrast to warfarin, because its anticoagulant effects are predictable, lab monitoring is not necessary. FDA approved on October 19, 2010.

Structure

Similar Structures

Synonyms

Ethyl 3-[[[4-[[[(hexyloxyl)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl](pyridin-2-yl)amino] propanoate

External IDs

BIBR 1048 / BIBR 1048 BS RS1 / BIBR-1048 / BIBR-1048-BS-RS1

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Dabigatran etexilate mesilate	SC7NUW5IIT	872728-81-9	XETBXHPXHHOLOE-UHFFFAOYSA-N

Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Pradaxa	Capsule	150 mg	Oral	Boehringer Ingelheim	2008-03-18	Not applicable
Pradaxa	Capsule	150 mg	Oral	Boehringer Ingelheim	2008-03-18	Not applicable
Pradaxa	Capsule	75 mg	Oral	Boehringer Ingelheim (Canada) Ltd Ltee	2008-07-03	Not applicable
Pradaxa	Capsule	150 mg/1	Oral	Rebel Distributors	2010-10-26	Not applicable
Pradaxa	Capsule	110 mg	Oral	Boehringer Ingelheim	2008-03-18	Not applicable
Pradaxa	Capsule	75 mg	Oral	Boehringer Ingelheim	2008-03-18	Not applicable
Pradaxa	Capsule	150 mg	Oral	Boehringer Ingelheim	2008-03-18	Not applicable
Pradaxa	Capsule	110 mg	Oral	Boehringer Ingelheim	2008-03-18	Not applicable
Pradaxa	Capsule	150 mg	Oral	Boehringer Ingelheim	2008-03-18	Not applicable
Pradaxa	Capsule	110 mg/1	Oral	Boehringer Ingelheim	2015-11-23	Not applicable

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Apo-dabigatran	Capsule	75 mg	Oral	Apotex Corporation	Not applicable	Not applicable
Apo-dabigatran	Capsule	150 mg	Oral	Apotex Corporation	Not applicable	Not applicable
Apo-dabigatran	Capsule	110 mg	Oral	Apotex Corporation	Not applicable	Not applicable
Teva-dabigatran	Capsule	75 mg	Oral	Teva	Not applicable	Not applicable
Teva-dabigatran	Capsule	150 mg	Oral	Teva	Not applicable	Not applicable

International/Other Brands

Pradax (Boehringer Ingelheim) / Rendix

Categories

UNII

2E18WX195X

CAS number

211915-06-9

Weight

Average: 627.7332
Monoisotopic: 627.316917457

Chemical Formula

C₃₄H₄₁N₇O₅

InChI Key

KSGXQBZTULBEEQ-UHFFFAOYSA-N

InChI

InChI=1S/C34H41N7O5/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44)

IUPAC Name

ethyl 3-(1-{2-[({4-[amino({[(hexyloxy)carbonyl]imino})methyl]phenyl}amino)methyl]-1-methyl-1H-1,3-benzodiazol-5-yl}-N-(pyridin-2-yl)formamido)propanoate

SMILES

CCCCCCOC(=O)N=C(N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=CC=CC=N3)N2C)C=C1

Pharmacology

Indication

Dabigatran is indicated for the prevention of venous thromboembolic events in patients who have undergone elective hip or knee replacement surgery (based on RE-NOVATE, RE-MODEL, and RE-MOBILIZE trials). In 2010, it was approved in the US and Canada for prevention of stroke and systemic embolism in patients with atrial fibrillation (approval based on the RE-LY trial). Contraindications: severe renal impairment (CrCL < 30 ml/min); haemorrhagic manifestations, bleeding diathesis or spontaneous or pharmacologic impairment of haemostasis; lesions at risk of clinically significant bleeding (e.g. extensive cerebral infarction (haemorrhagic or ischemic) in the last 6 months, active peptic ulcer disease); concomitant treatment with P-glycoprotein inhibitors (e.g. oral ketoconazole, verapamil); and those with known hypersensitivity to dabigatran, dabigatran etexilate or any ingredient used in the formulation or component of the container. As of December 2012, dabigatran is contraindicated in patients with mechanical prosthetic heart valves.

Structured Indications

Pharmacodynamics

Dabigatran directly inhibits thrombin in a concentration-dependent, reversible, specific, and competitive manner which results in a prolongation of aPTT (partial thromboplastin time), ECT (Ecarin clotting time), and TT (thrombin time). It may increase INR but this laboratory parameter is relatively insensitive to the activity of dabigatran.

Mechanism of action

Dabigatran etexilate is an inactive pro-drug that is converted to dabigatran, the active form, by esterase-catalyzed hydrolysis in the plasma and liver. Dabigatran, the main active principle in plasma, is a rapid-acting competitive and reversible direct inhibitor of thrombin. Thrombin, a serine protease, is responsible for the conversion of fibrinogen to fibrin in the coagulation cascade. Inhibition of thrombin consequently prevents thrombus development. Dabigatran inhibits free thrombin, fibrin-bound thrombin and thrombin-induced platelet aggregation.

Target	Actions	Organism
AProthrombin	inhibitor	Human

Absorption

Peak plasma concentrations were achieved in 6 hours in post surgical patients. In healthy patients, maximum concentrations were achieved in 0.5 to 2 hours. The absolute bioavailability of dabigatran in the body after administration of dabigatran etexilate was 6.5%. Food does not affect the bioavailability of dabigatran etexilate, but it delays the time to peak plasma concentrations by 2 hours. Oral bioavailability may increase by up to 75% when pellets are taken out of the hydroxypropylmethylcellulose (HPMC) capsule. Therefore, capsules should not be opened and pellets taken alone. Furthermore, although absorption of dabigatran etexilate is independent of gastrointestinal acidity, coadministration of pantoprazole (proton pump inhibitor) may reduce the bioavailability of dabigatran. Despite this finding, dose adjustment is not required.

Volume of distribution

Moderate tissue distribution with a Vd of 60-70L. Accumulation factor, twice daily dosing = 2

Protein binding

Relatively low binding (34-35%) to plasma proteins.

Metabolism

CYP450 enzymes are not involved in the metabolism of dabigatran thus is not expected to interact with drugs metabolized by CYP isoenzymes. Dabigatran is typically metabolised by esterases and microsomal carboxylesterases. Pharmacologically active acylglucoronides are formed via conjugation. Four positional isomers, 1-O, 2-O, 3-O, and 4-O, acylglucuronides exist, each accounting for less than 10% of total plasma dabagatran.

Route of elimination

Mainly excreted in urine (85%). Fecal excretion accounts for 6% of the orally administered dose. Dabigatran is primarily eliminated unchanged via the kidneys at a rate of 100 ml/min corresponding to the glomerular filtration rate.

Half life

12-14 hours in healthy volunteers. 14-17 hours in patients treated for prevention of venous thromboembolism following hip- or knee-replacement surgery.

Clearance

Not Available

Toxicity

The most common adverse reactions include dyspepsia or gastritis-like symptoms. The approximate lethal dose (LD50) in rats and mice was observed at single oral doses of > 2000 mg/kg. Oral doses of 600 mg/kg did not induce any toxicologically meaningful changes in dogs and Rhesus monkeys. Dabigatran was well-tolerated in rats and Rhesus monkeys during repeat-dose toxicity studies. No evidence of mutagenic potential.

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
(4R)-limonene	(4R)-limonene may increase the anticoagulant activities of Dabigatran etexilate.	Investigational
Abacavir	The serum concentration of Abacavir can be decreased when it is combined with Dabigatran etexilate.	Approved, Investigational
Abciximab	Dabigatran etexilate may increase the anticoagulant activities of Abciximab.	Approved
Abemaciclib	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Abemaciclib.	Approved, Investigational
Aceclofenac	Aceclofenac may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Acemetacin	The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Acemetacin.	Approved, Experimental, Investigational
Acenocoumarol	Dabigatran etexilate may increase the anticoagulant activities of Acenocoumarol.	Approved, Investigational
Acetaminophen	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Acetaminophen.	Approved
Acetylsalicylic acid	Acetylsalicylic acid may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Vet Approved
Adapalene	Adapalene may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Afatinib	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Afatinib.	Approved
Albendazole	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Albendazole.	Approved, Vet Approved
Alclofenac	Alclofenac may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Withdrawn
Aldosterone	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Aldosterone.	Experimental, Investigational
Alectinib	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Alectinib.	Approved, Investigational
Alfentanil	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Alfentanil.	Approved, Illicit
Alfuzosin	The serum concentration of Alfuzosin can be increased when it is combined with Dabigatran etexilate.	Approved, Investigational
Allylestrenol	The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Allylestrenol.	Approved
Almasilate	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Almasilate.	Approved, Experimental
Alminoprofen	Alminoprofen may increase the anticoagulant activities of Dabigatran etexilate.	Experimental
Aloglutamol	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Aloglutamol.	Approved
Aloxiprin	Aloxiprin may increase the anticoagulant activities of Dabigatran etexilate.	Experimental
Alprazolam	The serum concentration of Alprazolam can be increased when it is combined with Dabigatran etexilate.	Approved, Illicit, Investigational
Alprostadil	Alprostadil may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Alteplase	Alteplase may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Altrenogest	The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Altrenogest.	Vet Approved
Aluminium	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Aluminium.	Approved, Investigational
Aluminium acetoacetate	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Aluminium acetoacetate.	Experimental
Aluminium glycinate	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Aluminium glycinate.	Experimental
Aluminum hydroxide	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Aluminum hydroxide.	Approved, Investigational
Amantadine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Amantadine.	Approved
Ambroxol acefyllinate	The serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Dabigatran etexilate.	Experimental, Investigational
Amineptine	The serum concentration of Amineptine can be increased when it is combined with Dabigatran etexilate.	Illicit, Withdrawn
Aminohippuric acid	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Aminohippuric acid.	Approved, Investigational
Aminophylline	The serum concentration of Aminophylline can be decreased when it is combined with Dabigatran etexilate.	Approved
Aminosalicylic Acid	Aminosalicylic Acid may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Amiodarone	The serum concentration of Dabigatran etexilate can be increased when it is combined with Amiodarone.	Approved, Investigational
Amitriptyline	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Amitriptyline.	Approved
Amlodipine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Amlodipine.	Approved
Amoxapine	The serum concentration of Amoxapine can be increased when it is combined with Dabigatran etexilate.	Approved
Amprenavir	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Amprenavir.	Approved, Investigational
Amsacrine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Amsacrine.	Approved, Investigational
Anagrelide	Anagrelide may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Ancrod	Dabigatran etexilate may increase the anticoagulant activities of Ancrod.	Approved, Investigational
Andrographolide	Andrographolide may increase the anticoagulant activities of Dabigatran etexilate.	Investigational
Anisodamine	Anisodamine may increase the anticoagulant activities of Dabigatran etexilate.	Investigational
Anistreplase	Anistreplase may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Antipyrine	Antipyrine may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Antithrombin III human	Dabigatran etexilate may increase the anticoagulant activities of Antithrombin III human.	Approved
Apalutamide	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Apalutamide.	Approved, Investigational
Apixaban	Apixaban may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Apocynin	Apocynin may increase the anticoagulant activities of Dabigatran etexilate.	Investigational
Apremilast	Apremilast may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Aprotinin	The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Aprotinin.	Approved, Investigational, Withdrawn
Ardeparin	Dabigatran etexilate may increase the anticoagulant activities of Ardeparin.	Approved, Investigational, Withdrawn
Argatroban	Dabigatran etexilate may increase the anticoagulant activities of Argatroban.	Approved, Investigational
Astaxanthin	Astaxanthin may increase the anticoagulant activities of Dabigatran etexilate.	Investigational
Astemizole	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Astemizole.	Approved, Withdrawn
Asunaprevir	The serum concentration of Dabigatran etexilate can be increased when it is combined with Asunaprevir.	Approved, Investigational, Withdrawn
Atazanavir	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Atazanavir.	Approved, Investigational
Atenolol	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Atenolol.	Approved
Atorvastatin	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Atorvastatin.	Approved
Azapropazone	Azapropazone may increase the anticoagulant activities of Dabigatran etexilate.	Withdrawn
Azelastine	Azelastine may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Azficel-T	The risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Azficel-T.	Approved, Investigational
Azithromycin	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Azithromycin.	Approved
Balsalazide	Balsalazide may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Batroxobin	Batroxobin may increase the anticoagulant activities of Dabigatran etexilate.	Experimental
Becaplermin	Dabigatran etexilate may increase the anticoagulant activities of Becaplermin.	Approved, Investigational
Bemiparin	Bemiparin may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Bendazac	Bendazac may increase the anticoagulant activities of Dabigatran etexilate.	Experimental
Benorilate	Benorilate may increase the anticoagulant activities of Dabigatran etexilate.	Experimental
Benoxaprofen	Benoxaprofen may increase the anticoagulant activities of Dabigatran etexilate.	Withdrawn
Benzocaine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Benzocaine.	Approved, Investigational
Benzydamine	Benzydamine may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Bepridil	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Bepridil.	Approved, Withdrawn
Beraprost	Beraprost may increase the anticoagulant activities of Dabigatran etexilate.	Investigational
Bevonium	Bevonium may increase the anticoagulant activities of Dabigatran etexilate.	Experimental
Biperiden	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Biperiden.	Approved, Investigational
Bismuth Subcitrate	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Bismuth Subcitrate.	Approved, Investigational
Bismuth subnitrate	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Bismuth subnitrate.	Approved, Experimental
Bivalirudin	Dabigatran etexilate may increase the anticoagulant activities of Bivalirudin.	Approved, Investigational
Boceprevir	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Boceprevir.	Approved, Withdrawn
Bosutinib	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Bosutinib.	Approved
Brinase	Brinase may increase the anticoagulant activities of Dabigatran etexilate.	Experimental
Bromfenac	Bromfenac may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Bromocriptine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Bromocriptine.	Approved, Investigational
Bucillamine	Bucillamine may increase the anticoagulant activities of Dabigatran etexilate.	Investigational
Bufexamac	Bufexamac may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Experimental
Buflomedil	Buflomedil may increase the anticoagulant activities of Dabigatran etexilate.	Experimental
Bumadizone	Bumadizone may increase the anticoagulant activities of Dabigatran etexilate.	Experimental
Buprenorphine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Buprenorphine.	Approved, Illicit, Investigational, Vet Approved
Buspirone	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Buspirone.	Approved, Investigational
Butylphthalide	Butylphthalide may increase the anticoagulant activities of Dabigatran etexilate.	Investigational
Cabazitaxel	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Cabazitaxel.	Approved
Cabergoline	The serum concentration of Cabergoline can be increased when it is combined with Dabigatran etexilate.	Approved
Caffeine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Caffeine.	Approved
Calcium Carbonate	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Calcium Carbonate.	Approved, Investigational
Calcium silicate	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Calcium silicate.	Experimental
Canagliflozin	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Canagliflozin.	Approved
Candesartan	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Candesartan.	Experimental
Candesartan cilexetil	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Candesartan cilexetil.	Approved
Cangrelor	Cangrelor may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Caplacizumab	Caplacizumab may increase the anticoagulant activities of Dabigatran etexilate.	Investigational
Captopril	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Captopril.	Approved
Carbamazepine	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Carbamazepine.	Approved, Investigational
Carbaspirin calcium	Carbaspirin calcium may increase the anticoagulant activities of Dabigatran etexilate.	Experimental, Investigational
Carprofen	Carprofen may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Vet Approved, Withdrawn
Carvedilol	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Carvedilol.	Approved, Investigational
Caspofungin	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Caspofungin.	Approved
Castanospermine	Castanospermine may increase the anticoagulant activities of Dabigatran etexilate.	Experimental
Celecoxib	Celecoxib may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Certoparin	Dabigatran etexilate may increase the anticoagulant activities of Certoparin.	Approved, Investigational
Chloroquine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Chloroquine.	Approved, Investigational, Vet Approved
Chlorotrianisene	The serum concentration of Chlorotrianisene can be decreased when it is combined with Dabigatran etexilate.	Investigational, Withdrawn
Chlorpromazine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Chlorpromazine.	Approved, Investigational, Vet Approved
Chlorpropamide	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Chlorpropamide.	Approved, Investigational
Chlorprothixene	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Chlorprothixene.	Approved, Investigational, Withdrawn
Cholesterol	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Cholesterol.	Approved, Experimental, Investigational
Cholic Acid	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Cholic Acid.	Approved
Choline magnesium trisalicylate	Choline magnesium trisalicylate may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Cilazapril	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Cilazapril.	Approved
Cilostazol	Cilostazol may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Cimetidine	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Cimetidine.	Approved, Investigational
Ciprofloxacin	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ciprofloxacin.	Approved, Investigational
Citalopram	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Citalopram.	Approved
Citric Acid	Dabigatran etexilate may increase the anticoagulant activities of Citric Acid.	Approved, Nutraceutical, Vet Approved
Clarithromycin	The serum concentration of Dabigatran etexilate can be increased when it is combined with Clarithromycin.	Approved
Clofazimine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Clofazimine.	Approved, Investigational
Clomipramine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Clomipramine.	Approved, Investigational, Vet Approved
Clonixin	Clonixin may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Clopidogrel	Clopidogrel may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Cloricromen	Cloricromen may increase the anticoagulant activities of Dabigatran etexilate.	Experimental
Clorindione	Clorindione may increase the anticoagulant activities of Dabigatran etexilate.	Experimental
Clotrimazole	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Clotrimazole.	Approved, Vet Approved
Cobicistat	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Cobicistat.	Approved
Colchicine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Colchicine.	Approved
Colforsin	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Colforsin.	Experimental, Investigational
Collagenase clostridium histolyticum	The risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Collagenase clostridium histolyticum.	Approved, Investigational
Conjugated estrogens	The serum concentration of Conjugated estrogens can be decreased when it is combined with Dabigatran etexilate.	Approved
Crizotinib	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Crizotinib.	Approved
Curcumin	Curcumin may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Cyclobenzaprine	The serum concentration of Cyclobenzaprine can be increased when it is combined with Dabigatran etexilate.	Approved
Cyclophosphamide	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Cyclophosphamide.	Approved, Investigational
Cyclosporine	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Cyclosporine.	Approved, Investigational, Vet Approved
Daclatasvir	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Daclatasvir.	Approved, Investigational
Dactinomycin	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Dactinomycin.	Approved, Investigational
Daidzein	Daidzein may decrease the anticoagulant activities of Dabigatran etexilate.	Experimental
Dalteparin	Dabigatran etexilate may increase the anticoagulant activities of Dalteparin.	Approved
Danaparoid	Dabigatran etexilate may increase the anticoagulant activities of Danaparoid.	Approved, Withdrawn
Darexaban	Dabigatran etexilate may increase the anticoagulant activities of Darexaban.	Investigational
Dasatinib	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Dasatinib.	Approved, Investigational
Daunorubicin	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Daunorubicin.	Approved
Deferasirox	The risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Deferasirox.	Approved, Investigational
Defibrotide	Defibrotide may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Delavirdine	The serum concentration of Delavirdine can be decreased when it is combined with Dabigatran etexilate.	Approved
Demegestone	The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Demegestone.	Experimental
Deoxycholic Acid	The risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Deoxycholic Acid.	Approved
Dersalazine	Dersalazine may increase the anticoagulant activities of Dabigatran etexilate.	Investigational
Desipramine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Desipramine.	Approved, Investigational
Desirudin	Dabigatran etexilate may increase the anticoagulant activities of Desirudin.	Approved
Desloratadine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Desloratadine.	Approved, Investigational
Desmoteplase	Desmoteplase may increase the anticoagulant activities of Dabigatran etexilate.	Investigational
Desogestrel	The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Desogestrel.	Approved
Dexamethasone	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Dexamethasone.	Approved, Investigational, Vet Approved
Dexlansoprazole	The serum concentration of the active metabolites of Dabigatran etexilate can be reduced when Dabigatran etexilate is used in combination with Dexlansoprazole resulting in a loss in efficacy.	Approved, Investigational
Dexrabeprazole	The serum concentration of the active metabolites of Dabigatran etexilate can be reduced when Dabigatran etexilate is used in combination with Dexrabeprazole resulting in a loss in efficacy.	Experimental
Dextran	Dabigatran etexilate may increase the anticoagulant activities of Dextran.	Approved, Investigational, Vet Approved
Dextromethorphan	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Dextromethorphan.	Approved
Dibenzepin	The serum concentration of Dibenzepin can be increased when it is combined with Dabigatran etexilate.	Experimental
Diclofenac	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Diclofenac.	Approved, Vet Approved
Dicoumarol	Dabigatran etexilate may increase the anticoagulant activities of Dicoumarol.	Approved
Dienestrol	The serum concentration of Dienestrol can be decreased when it is combined with Dabigatran etexilate.	Approved, Investigational
Dienogest	The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Dienogest.	Approved
Diethylstilbestrol	The serum concentration of Diethylstilbestrol can be decreased when it is combined with Dabigatran etexilate.	Approved, Investigational
Difenpiramide	Difenpiramide may increase the anticoagulant activities of Dabigatran etexilate.	Experimental
Diflunisal	Diflunisal may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Digoxin	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Digoxin.	Approved
Dihydroergotamine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Dihydroergotamine.	Approved, Investigational
Diltiazem	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Diltiazem.	Approved, Investigational
Diphenadione	Diphenadione may increase the anticoagulant activities of Dabigatran etexilate.	Experimental
Dipyridamole	Dipyridamole may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Ditazole	Ditazole may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Withdrawn
Dosulepin	The serum concentration of Dosulepin can be increased when it is combined with Dabigatran etexilate.	Approved
Doxazosin	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Doxazosin.	Approved
Doxepin	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Doxepin.	Approved, Investigational
Doxorubicin	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Doxorubicin.	Approved, Investigational
Dronabinol	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Dronabinol.	Approved, Illicit
Dronedarone	The serum concentration of Dabigatran etexilate can be increased when it is combined with Dronedarone.	Approved
Drotrecogin alfa	Drotrecogin alfa may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational, Withdrawn
Droxicam	Droxicam may increase the anticoagulant activities of Dabigatran etexilate.	Withdrawn
Duvelisib	Duvelisib may increase the anticoagulant activities of Dabigatran etexilate.	Investigational
Dydrogesterone	The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Dydrogesterone.	Approved, Investigational, Withdrawn
Dyphylline	The serum concentration of Dyphylline can be decreased when it is combined with Dabigatran etexilate.	Approved
E-6201	E-6201 may increase the anticoagulant activities of Dabigatran etexilate.	Investigational
Edetic Acid	Dabigatran etexilate may increase the anticoagulant activities of Edetic Acid.	Approved, Vet Approved
Edoxaban	Dabigatran etexilate may increase the anticoagulant activities of Edoxaban.	Approved
Enalapril	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Enalapril.	Approved, Vet Approved
Enasidenib	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Enasidenib.	Approved, Investigational
Enfuvirtide	The serum concentration of Enfuvirtide can be increased when it is combined with Dabigatran etexilate.	Approved, Investigational
Enoxaparin	Dabigatran etexilate may increase the anticoagulant activities of Enoxaparin.	Approved
Enzalutamide	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Enzalutamide.	Approved
Epimestrol	Epimestrol may decrease the anticoagulant activities of Dabigatran etexilate.	Experimental
Epinastine	Epinastine may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Epirizole	Epirizole may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Eplivanserin	Eplivanserin may increase the anticoagulant activities of Dabigatran etexilate.	Investigational
eplivanserine	eplivanserine may increase the anticoagulant activities of Dabigatran etexilate.	Investigational
Epoprostenol	Epoprostenol may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Eptifibatide	Eptifibatide may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Equol	Equol may decrease the anticoagulant activities of Dabigatran etexilate.	Investigational
Ergoloid mesylate	The serum concentration of Ergoloid mesylate can be increased when it is combined with Dabigatran etexilate.	Approved
Ergonovine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ergonovine.	Approved
Ergotamine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ergotamine.	Approved
Erythromycin	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Erythromycin.	Approved, Investigational, Vet Approved
Esmirtazapine	The serum concentration of Esmirtazapine can be increased when it is combined with Dabigatran etexilate.	Investigational
Esomeprazole	The serum concentration of the active metabolites of Dabigatran etexilate can be reduced when Dabigatran etexilate is used in combination with Esomeprazole resulting in a loss in efficacy.	Approved, Investigational
Estradiol	The serum concentration of Estradiol can be decreased when it is combined with Dabigatran etexilate.	Approved, Investigational, Vet Approved
Estradiol acetate	Estradiol acetate may decrease the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational, Vet Approved
Estradiol cypionate	Estradiol cypionate may decrease the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational, Vet Approved
Estradiol valerate	Estradiol valerate may decrease the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational, Vet Approved
Estramustine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Estramustine.	Approved, Investigational
Estriol	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Estriol.	Approved, Investigational, Vet Approved
Estrogens, esterified	The serum concentration of Estrogens, esterified can be decreased when it is combined with Dabigatran etexilate.	Approved
Estrone	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Estrone.	Approved
Estrone sulfate	The serum concentration of Estrone sulfate can be decreased when it is combined with Dabigatran etexilate.	Approved
Etanercept	Etanercept may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Ethenzamide	Ethenzamide may increase the anticoagulant activities of Dabigatran etexilate.	Experimental
Ethinyl Estradiol	The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Dabigatran etexilate.	Approved
Ethyl biscoumacetate	Dabigatran etexilate may increase the anticoagulant activities of Ethyl biscoumacetate.	Withdrawn
Ethynodiol	The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Ethynodiol.	Experimental
Etodolac	Etodolac may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational, Vet Approved
Etofenamate	Etofenamate may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Etonogestrel	The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Etonogestrel.	Approved, Investigational
Etoposide	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Etoposide.	Approved
Etoricoxib	Etoricoxib may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Etravirine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Etravirine.	Approved
Evening primrose oil	Evening primrose oil may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Exisulind	Exisulind may increase the anticoagulant activities of Dabigatran etexilate.	Investigational
Felbinac	Felbinac may increase the anticoagulant activities of Dabigatran etexilate.	Experimental
Felodipine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Felodipine.	Approved, Investigational
Fenbufen	Fenbufen may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Fenoprofen	Fenoprofen may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Fentanyl	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Fentanyl.	Approved, Illicit, Investigational, Vet Approved
Fentiazac	Fentiazac may increase the anticoagulant activities of Dabigatran etexilate.	Experimental
Feprazone	Feprazone may increase the anticoagulant activities of Dabigatran etexilate.	Experimental
Ferulic acid	Dabigatran etexilate may increase the anticoagulant activities of Ferulic acid.	Experimental
Fexofenadine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Fexofenadine.	Approved, Investigational
Fibrinolysin	Fibrinolysin may increase the anticoagulant activities of Dabigatran etexilate.	Investigational
Fidaxomicin	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Fidaxomicin.	Approved
Floctafenine	Floctafenine may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Withdrawn
Fluconazole	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Fluconazole.	Approved, Investigational
Fluindione	Dabigatran etexilate may increase the anticoagulant activities of Fluindione.	Approved, Investigational
Flunixin	Flunixin may increase the anticoagulant activities of Dabigatran etexilate.	Vet Approved
Flunoxaprofen	Flunoxaprofen may increase the anticoagulant activities of Dabigatran etexilate.	Experimental
Fluoxetine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Fluoxetine.	Approved, Vet Approved
Flupentixol	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Flupentixol.	Approved, Investigational, Withdrawn
Fluphenazine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Fluphenazine.	Approved
Flurazepam	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Flurazepam.	Approved, Illicit, Investigational
Flurbiprofen	Flurbiprofen may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Fluvoxamine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Fluvoxamine.	Approved, Investigational
Fondaparinux	Dabigatran etexilate may increase the anticoagulant activities of Fondaparinux.	Approved, Investigational
Fondaparinux sodium	Dabigatran etexilate may increase the anticoagulant activities of Fondaparinux sodium.	Approved, Investigational
Gabexate	Dabigatran etexilate may increase the anticoagulant activities of Gabexate.	Investigational
Garlic	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Garlic.	Approved
Gefitinib	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Gefitinib.	Approved, Investigational
Genistein	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Genistein.	Investigational
Gestodene	The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Gestodene.	Approved, Investigational
Gestonorone	The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Gestonorone.	Experimental
Gestrinone	The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Gestrinone.	Approved
Glecaprevir	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Glecaprevir.	Approved, Investigational
Glyburide	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Glyburide.	Approved
Glycerin	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Glycerin.	Approved, Investigational
Gramicidin D	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Gramicidin D.	Approved
Grepafloxacin	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Grepafloxacin.	Approved, Investigational, Withdrawn
Guacetisal	Guacetisal may increase the anticoagulant activities of Dabigatran etexilate.	Experimental
Haloperidol	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Haloperidol.	Approved
Hemin	Hemin may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Hemoglobin crosfumaril	Hemoglobin crosfumaril may increase the anticoagulant activities of Dabigatran etexilate.	Experimental
Heparin	Dabigatran etexilate may increase the anticoagulant activities of Heparin.	Approved, Investigational
Hexestrol	The serum concentration of Hexestrol can be decreased when it is combined with Dabigatran etexilate.	Withdrawn
Higenamine	Higenamine may increase the anticoagulant activities of Dabigatran etexilate.	Investigational
Hydrocortisone	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Hydrocortisone.	Approved, Vet Approved
Hydrotalcite	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Hydrotalcite.	Approved, Experimental, Investigational
Hydroxyprogesterone caproate	The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Hydroxyprogesterone caproate.	Approved, Investigational
Hydroxytyrosol	Hydroxytyrosol may increase the anticoagulant activities of Dabigatran etexilate.	Investigational
Ibritumomab tiuxetan	The risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Ibritumomab tiuxetan.	Approved, Investigational
Ibrutinib	The risk or severity of adverse effects can be increased when Ibrutinib is combined with Dabigatran etexilate.	Approved
Ibudilast	Ibudilast may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Ibuprofen	Ibuprofen may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Ibuproxam	Ibuproxam may increase the anticoagulant activities of Dabigatran etexilate.	Withdrawn
Icatibant	Icatibant may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Icosapent ethyl	Icosapent ethyl may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational, Nutraceutical
Idelalisib	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Idelalisib.	Approved
Idraparinux	Dabigatran etexilate may increase the anticoagulant activities of Idraparinux.	Investigational
Ifenprodil	Ifenprodil may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational, Withdrawn
Ifetroban	Ifetroban may increase the anticoagulant activities of Dabigatran etexilate.	Investigational
Iloprost	Iloprost may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Imatinib	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Imatinib.	Approved
Imidazole salicylate	Imidazole salicylate may increase the anticoagulant activities of Dabigatran etexilate.	Experimental
Imipramine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Imipramine.	Approved
Indinavir	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Indinavir.	Approved
Indobufen	Indobufen may increase the anticoagulant activities of Dabigatran etexilate.	Investigational
Indomethacin	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Indomethacin.	Approved, Investigational
Indoprofen	Indoprofen may increase the anticoagulant activities of Dabigatran etexilate.	Withdrawn
Iprindole	The serum concentration of Iprindole can be increased when it is combined with Dabigatran etexilate.	Experimental
Isavuconazole	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Isavuconazole.	Approved, Investigational
Isavuconazonium	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Isavuconazonium.	Approved, Investigational
Isoxicam	Isoxicam may increase the anticoagulant activities of Dabigatran etexilate.	Withdrawn
Itraconazole	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Itraconazole.	Approved, Investigational
Ivacaftor	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ivacaftor.	Approved
Ivermectin	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ivermectin.	Approved, Investigational, Vet Approved
Kebuzone	Kebuzone may increase the anticoagulant activities of Dabigatran etexilate.	Experimental
Ketamine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ketamine.	Approved, Vet Approved
Ketanserin	Ketanserin may increase the anticoagulant activities of Dabigatran etexilate.	Investigational
Ketoconazole	The serum concentration of Dabigatran etexilate can be increased when it is combined with Ketoconazole.	Approved, Investigational
Ketoprofen	Ketoprofen may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Vet Approved
Ketorolac	Ketorolac may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Lansoprazole	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lansoprazole.	Approved, Investigational
Lapatinib	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lapatinib.	Approved, Investigational
Leflunomide	Leflunomide may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Lepirudin	Dabigatran etexilate may increase the anticoagulant activities of Lepirudin.	Approved
Letaxaban	Dabigatran etexilate may increase the anticoagulant activities of Letaxaban.	Investigational
Letermovir	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Letermovir.	Approved, Investigational
Levofloxacin	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Levofloxacin.	Approved, Investigational
Levonorgestrel	The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Levonorgestrel.	Approved, Investigational
Levothyroxine	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Levothyroxine.	Approved
Lidocaine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lidocaine.	Approved, Vet Approved
Limaprost	The risk or severity of adverse effects can be increased when Limaprost is combined with Dabigatran etexilate.	Approved, Investigational
Linsidomine	Linsidomine may increase the anticoagulant activities of Dabigatran etexilate.	Experimental
Liothyronine	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Liothyronine.	Approved, Vet Approved
Liotrix	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Liotrix.	Approved
Lisofylline	Lisofylline may increase the anticoagulant activities of Dabigatran etexilate.	Investigational
Lofepramine	The serum concentration of Lofepramine can be increased when it is combined with Dabigatran etexilate.	Experimental
Lomitapide	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lomitapide.	Approved, Investigational
Lonazolac	Lonazolac may increase the anticoagulant activities of Dabigatran etexilate.	Experimental
Loperamide	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Loperamide.	Approved
Lopinavir	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lopinavir.	Approved
Loratadine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Loratadine.	Approved, Investigational
Lornoxicam	Lornoxicam may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Losartan	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Losartan.	Approved
Lovastatin	The serum concentration of Lovastatin can be increased when it is combined with Dabigatran etexilate.	Approved, Investigational
Loxoprofen	Loxoprofen may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Lumacaftor	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Lumacaftor.	Approved
Lumiracoxib	Lumiracoxib may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Magaldrate	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Magaldrate.	Approved, Withdrawn
Magnesium hydroxide	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Magnesium hydroxide.	Approved, Investigational
Magnesium oxide	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Magnesium oxide.	Approved
Magnesium peroxide	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Magnesium peroxide.	Experimental
Magnesium salicylate	Magnesium salicylate may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Magnesium silicate	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Magnesium silicate.	Approved, Experimental
Magnesium Trisilicate	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Magnesium Trisilicate.	Approved
Maprotiline	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Maprotiline.	Approved, Investigational
Masoprocol	Masoprocol may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Mebendazole	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Mebendazole.	Approved, Vet Approved
Meclofenamic acid	Meclofenamic acid may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Vet Approved
Medrogestone	The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Medrogestone.	Approved
Medroxyprogesterone acetate	The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Medroxyprogesterone acetate.	Approved, Investigational
Mefenamic acid	Mefenamic acid may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Mefloquine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Mefloquine.	Approved, Investigational
Megestrol acetate	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Megestrol acetate.	Approved, Investigational, Vet Approved
Melagatran	Dabigatran etexilate may increase the anticoagulant activities of Melagatran.	Experimental
Meloxicam	Meloxicam may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Vet Approved
Meprobamate	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Meprobamate.	Approved, Illicit
Mesalazine	Mesalazine may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Mestranol	The serum concentration of Mestranol can be decreased when it is combined with Dabigatran etexilate.	Approved
Metamizole	Metamizole may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational, Withdrawn
Methadone	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Methadone.	Approved
Methallenestril	The serum concentration of Methallenestril can be decreased when it is combined with Dabigatran etexilate.	Experimental
Methyl salicylate	Methyl salicylate may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Vet Approved
Methylergometrine	The serum concentration of Methylergometrine can be increased when it is combined with Dabigatran etexilate.	Approved
Methylestrenolone	The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Methylestrenolone.	Experimental
Metoprolol	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Metoprolol.	Approved, Investigational
Mibefradil	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Mibefradil.	Investigational, Withdrawn
Miconazole	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Miconazole.	Approved, Investigational, Vet Approved
Midazolam	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Midazolam.	Approved, Illicit
Mifepristone	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Mifepristone.	Approved, Investigational
Milrinone	Milrinone may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Mirtazapine	The serum concentration of Mirtazapine can be increased when it is combined with Dabigatran etexilate.	Approved
Mitomycin	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Mitomycin.	Approved
Mitoxantrone	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Mitoxantrone.	Approved, Investigational
Mizoribine	Mizoribine may increase the anticoagulant activities of Dabigatran etexilate.	Investigational
Mofebutazone	Mofebutazone may increase the anticoagulant activities of Dabigatran etexilate.	Experimental
Morphine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Morphine.	Approved, Investigational
Moxestrol	Moxestrol may decrease the anticoagulant activities of Dabigatran etexilate.	Experimental
Mycophenolate mofetil	Mycophenolate mofetil may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Mycophenolic acid	Mycophenolic acid may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Nabumetone	Nabumetone may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Nadroparin	Dabigatran etexilate may increase the anticoagulant activities of Nadroparin.	Approved, Investigational
Nafamostat	Dabigatran etexilate may increase the anticoagulant activities of Nafamostat.	Approved, Investigational
Naftifine	Naftifine may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Naftopidil	Naftopidil may increase the anticoagulant activities of Dabigatran etexilate.	Investigational
Naltrexone	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Naltrexone.	Approved, Investigational, Vet Approved
Naproxen	Naproxen may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Vet Approved
Naringenin	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Naringenin.	Experimental
Nefazodone	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Nelfinavir.	Approved
Neostigmine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Neostigmine.	Approved, Vet Approved
Nepafenac	Nepafenac may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Nicardipine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Nicardipine.	Approved, Investigational
Nifedipine	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Nifedipine.	Approved
Nifenazone	Nifenazone may increase the anticoagulant activities of Dabigatran etexilate.	Experimental
Niflumic Acid	Niflumic Acid may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Nilotinib	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Nilotinib.	Approved, Investigational
Nimesulide	Nimesulide may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational, Withdrawn
Nintedanib	The risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Nintedanib.	Approved
Nisoldipine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Nisoldipine.	Approved
Nitrazepam	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Nitrazepam.	Approved
Nitrendipine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Nitrendipine.	Approved, Investigational
Nitroaspirin	Nitroaspirin may increase the anticoagulant activities of Dabigatran etexilate.	Investigational
Nomegestrol	The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Nomegestrol.	Approved
Norethisterone	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Norethisterone.	Approved
Norgestrienone	The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Norgestrienone.	Experimental
Nortriptyline	The serum concentration of Nortriptyline can be increased when it is combined with Dabigatran etexilate.	Approved
Obinutuzumab	The risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Obinutuzumab.	Approved, Investigational
Olopatadine	Olopatadine may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Olsalazine	Olsalazine may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Omacetaxine mepesuccinate	The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Omacetaxine mepesuccinate.	Approved, Investigational
Omega-3 fatty acids	Omega-3 fatty acids may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Nutraceutical
Omega-3-carboxylic acids	The therapeutic efficacy of Dabigatran etexilate can be increased when used in combination with Omega-3-carboxylic acids.	Approved, Investigational
Omeprazole	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Omeprazole.	Approved, Investigational, Vet Approved
Opipramol	The serum concentration of Opipramol can be increased when it is combined with Dabigatran etexilate.	Investigational
Orgotein	Orgotein may increase the anticoagulant activities of Dabigatran etexilate.	Vet Approved
Otamixaban	Dabigatran etexilate may increase the anticoagulant activities of Otamixaban.	Investigational
Oxaprozin	Oxaprozin may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Oxyphenbutazone	Oxyphenbutazone may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Withdrawn
Ozagrel	Ozagrel may increase the anticoagulant activities of Dabigatran etexilate.	Investigational
P-Nitrophenol	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with P-Nitrophenol.	Experimental
Paclitaxel	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Paclitaxel.	Approved, Vet Approved
Palmitic Acid	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Palmitic Acid.	Approved, Experimental
Pantoprazole	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Pantoprazole.	Approved
Parecoxib	Parecoxib may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Parnaparin	Parnaparin may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Paroxetine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Paroxetine.	Approved, Investigational
Parthenolide	Parthenolide may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Pentaerythritol Tetranitrate	Dabigatran etexilate may increase the anticoagulant activities of Pentaerythritol Tetranitrate.	Approved
Pentosan Polysulfate	Dabigatran etexilate may increase the anticoagulant activities of Pentosan Polysulfate.	Approved
Pentoxifylline	Pentoxifylline may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Perindopril	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Perindopril.	Approved
Pethidine	The risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Pethidine.	Approved
Phenindione	Dabigatran etexilate may increase the anticoagulant activities of Phenindione.	Approved, Investigational
Phenobarbital	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Phenobarbital.	Approved, Investigational
Phenprocoumon	Dabigatran etexilate may increase the anticoagulant activities of Phenprocoumon.	Approved, Investigational
Phenyl aminosalicylate	Phenyl aminosalicylate may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Phenylbutazone	Phenylbutazone may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Vet Approved
Pibrentasvir	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Pibrentasvir.	Approved, Investigational
Picotamide	Picotamide may increase the anticoagulant activities of Dabigatran etexilate.	Experimental
Pimecrolimus	Pimecrolimus may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Pimozide	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Pimozide.	Approved
Pirfenidone	Pirfenidone may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Piroxicam	Piroxicam may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Pirprofen	Pirprofen may increase the anticoagulant activities of Dabigatran etexilate.	Experimental
Pitolisant	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Pitolisant.	Approved, Investigational
Platelet Activating Factor	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Platelet Activating Factor.	Experimental
Polyestradiol phosphate	Polyestradiol phosphate may decrease the anticoagulant activities of Dabigatran etexilate.	Approved
Ponatinib	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ponatinib.	Approved, Investigational
Posaconazole	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Posaconazole.	Approved, Investigational, Vet Approved
Pranoprofen	Pranoprofen may increase the anticoagulant activities of Dabigatran etexilate.	Experimental, Investigational
Prasugrel	Prasugrel may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Pravastatin	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Pravastatin.	Approved
Prazosin	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Prazosin.	Approved
Prednisone	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Prednisone.	Approved, Vet Approved
Probenecid	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Probenecid.	Approved, Investigational
Progesterone	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Progesterone.	Approved, Vet Approved
Proglumetacin	Proglumetacin may increase the anticoagulant activities of Dabigatran etexilate.	Experimental
Promegestone	The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Promegestone.	Experimental
Promestriene	Promestriene may decrease the anticoagulant activities of Dabigatran etexilate.	Investigational
Promethazine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Promethazine.	Approved, Investigational
Propacetamol	Propacetamol may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Propafenone	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Propafenone.	Approved
Propranolol	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Propranolol.	Approved, Investigational
Propyphenazone	Propyphenazone may increase the anticoagulant activities of Dabigatran etexilate.	Experimental
Proquazone	Proquazone may increase the anticoagulant activities of Dabigatran etexilate.	Experimental
Protein C	Dabigatran etexilate may increase the anticoagulant activities of Protein C.	Approved
Protein S human	Dabigatran etexilate may increase the anticoagulant activities of Protein S human.	Approved
Protocatechualdehyde	Dabigatran etexilate may increase the anticoagulant activities of Protocatechualdehyde.	Approved
Protriptyline	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Protriptyline.	Approved
PTC299	PTC299 may increase the anticoagulant activities of Dabigatran etexilate.	Investigational
Quercetin	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Quercetin.	Experimental, Investigational
Quinacrine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Quinacrine.	Approved, Investigational
Quinestrol	Quinestrol may decrease the anticoagulant activities of Dabigatran etexilate.	Approved
Quinidine	The serum concentration of Dabigatran etexilate can be increased when it is combined with Quinidine.	Approved, Investigational
Quinine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Quinine.	Approved
Rabeprazole	The serum concentration of the active metabolites of Dabigatran etexilate can be reduced when Dabigatran etexilate is used in combination with Rabeprazole resulting in a loss in efficacy.	Approved, Investigational
Ramatroban	Ramatroban may increase the anticoagulant activities of Dabigatran etexilate.	Investigational
Ranitidine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ranitidine.	Approved
Ranolazine	The serum concentration of Dabigatran etexilate can be increased when it is combined with Ranolazine.	Approved, Investigational
Reboxetine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Reboxetine.	Approved, Investigational
Regorafenib	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Regorafenib.	Approved
Relcovaptan	Relcovaptan may increase the anticoagulant activities of Dabigatran etexilate.	Investigational
Reserpine	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Reserpine.	Approved, Investigational
Resveratrol	Resveratrol may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Experimental, Investigational
Reteplase	Reteplase may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Reviparin	Dabigatran etexilate may increase the anticoagulant activities of Reviparin.	Approved, Investigational
Ridogrel	Ridogrel may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Rifampicin	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Rifampicin.	Approved
Rilpivirine	The serum concentration of Dabigatran etexilate can be increased when it is combined with Rilpivirine.	Approved
Riociguat	The serum concentration of Riociguat can be increased when it is combined with Dabigatran etexilate.	Approved
Ritonavir	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Ritonavir.	Approved, Investigational
Rivaroxaban	Dabigatran etexilate may increase the anticoagulant activities of Rivaroxaban.	Approved
Rofecoxib	Rofecoxib may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational, Withdrawn
Rolapitant	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Rolapitant.	Approved, Investigational
Rosiglitazone	Rosiglitazone may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Rucaparib	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Rucaparib.	Approved, Investigational
Salicylamide	Salicylamide may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Salicylic acid	Salicylic acid may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational, Vet Approved
Salsalate	Salsalate may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Saquinavir	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Saquinavir.	Approved, Investigational
Sarpogrelate	Sarpogrelate may increase the anticoagulant activities of Dabigatran etexilate.	Investigational
Saruplase	Saruplase may increase the anticoagulant activities of Dabigatran etexilate.	Experimental
Scopolamine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Scopolamine.	Approved, Investigational
Secoisolariciresinol	Secoisolariciresinol may decrease the anticoagulant activities of Dabigatran etexilate.	Investigational
Selegiline	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Selegiline.	Approved, Investigational, Vet Approved
Selexipag	Selexipag may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Semapimod	Semapimod may increase the anticoagulant activities of Dabigatran etexilate.	Investigational
Seratrodast	Seratrodast may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Serrapeptase	Serrapeptase may increase the anticoagulant activities of Dabigatran etexilate.	Investigational
Sertraline	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Sertraline.	Approved
Sevoflurane	Sevoflurane may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Vet Approved
Sildenafil	The serum concentration of Sildenafil can be increased when it is combined with Dabigatran etexilate.	Approved, Investigational
Simeprevir	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Simeprevir.	Approved
Simvastatin	The serum concentration of Simvastatin can be increased when it is combined with Dabigatran etexilate.	Approved
Sirolimus	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Sirolimus.	Approved, Investigational
Sodium bicarbonate	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Sodium bicarbonate.	Approved
Sorafenib	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Sorafenib.	Approved, Investigational
Spironolactone	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Spironolactone.	Approved
SRT501	SRT501 may increase the anticoagulant activities of Dabigatran etexilate.	Investigational
St. John's Wort	The metabolism of Dabigatran etexilate can be increased when combined with St. John's Wort.	Approved, Investigational, Nutraceutical
Staurosporine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Staurosporine.	Experimental
Streptokinase	Streptokinase may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Streptozocin	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Streptozocin.	Approved, Investigational
Sugammadex	Sugammadex may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Sulfasalazine	Sulfasalazine may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Sulfinpyrazone	Sulfinpyrazone may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Sulindac	Sulindac may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Sulodexide	Dabigatran etexilate may increase the anticoagulant activities of Sulodexide.	Approved, Investigational
Sumatriptan	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Sumatriptan.	Approved, Investigational
Sunitinib	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Sunitinib.	Approved, Investigational
Suprofen	Suprofen may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Withdrawn
Suxibuzone	Suxibuzone may increase the anticoagulant activities of Dabigatran etexilate.	Experimental
Synthetic Conjugated Estrogens, A	The serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Dabigatran etexilate.	Approved
Synthetic Conjugated Estrogens, B	Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Dabigatran etexilate.	Approved
Tacrine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Tacrine.	Investigational, Withdrawn
Tacrolimus	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Tacrolimus.	Approved, Investigational
Tamoxifen	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Tamoxifen.	Approved
Tarenflurbil	Tarenflurbil may increase the anticoagulant activities of Dabigatran etexilate.	Investigational
Taurocholic Acid	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Taurocholic Acid.	Experimental
Telaprevir	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Telaprevir.	Approved, Withdrawn
Telmisartan	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Telmisartan.	Approved, Investigational
Temsirolimus	The risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Temsirolimus.	Approved
Tenecteplase	Tenecteplase may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Tenidap	Tenidap may increase the anticoagulant activities of Dabigatran etexilate.	Experimental
Tenoxicam	Tenoxicam may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Tepoxalin	Tepoxalin may increase the anticoagulant activities of Dabigatran etexilate.	Vet Approved
Terazosin	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Terazosin.	Approved
Terfenadine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Terfenadine.	Approved, Withdrawn
Teriflunomide	Teriflunomide may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Tesmilifene	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Tesmilifene.	Investigational
Testosterone	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Testosterone.	Approved, Investigational
Testosterone cypionate	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Testosterone cypionate.	Approved
Testosterone enanthate	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Testosterone enanthate.	Approved
Testosterone undecanoate	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Testosterone undecanoate.	Approved, Investigational
Theophylline	The serum concentration of Theophylline can be decreased when it is combined with Dabigatran etexilate.	Approved
Tianeptine	The serum concentration of Tianeptine can be increased when it is combined with Dabigatran etexilate.	Approved, Investigational
Tiaprofenic acid	Tiaprofenic acid may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Tibolone	Tibolone may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Ticagrelor	Ticagrelor may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Ticlopidine	Ticlopidine may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Tinoridine	Tinoridine may increase the anticoagulant activities of Dabigatran etexilate.	Investigational
Tinzaparin	Tinzaparin may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Tioclomarol	Tioclomarol may increase the anticoagulant activities of Dabigatran etexilate.	Experimental
Tipranavir	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Tipranavir.	Approved, Investigational
Tirofiban	Tirofiban may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Tolfenamic Acid	Tolfenamic Acid may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Tolmetin	Tolmetin may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Tolvaptan	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Tolvaptan.	Approved
Tositumomab	The risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Tositumomab.	Approved, Investigational
Tranilast	Tranilast may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Trapidil	Trapidil may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Trazodone	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Trazodone.	Approved, Investigational
Treprostinil	Treprostinil may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Triazolam	The serum concentration of Triazolam can be increased when it is combined with Dabigatran etexilate.	Approved, Investigational
Tribenoside	Tribenoside may increase the anticoagulant activities of Dabigatran etexilate.	Experimental
Trifluoperazine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Trifluoperazine.	Approved, Investigational
Triflupromazine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Triflupromazine.	Approved, Vet Approved
Triflusal	Triflusal may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Trimethoprim	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Trimethoprim.	Approved, Vet Approved
Trimipramine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Trimipramine.	Approved
Triptolide	Triptolide may increase the anticoagulant activities of Dabigatran etexilate.	Investigational
Trolamine salicylate	Trolamine salicylate may increase the anticoagulant activities of Dabigatran etexilate.	Approved
Troleandomycin	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Troleandomycin.	Approved
Tromethamine	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Tromethamine.	Approved
Troxerutin	Dabigatran etexilate may increase the anticoagulant activities of Troxerutin.	Investigational
Urokinase	Urokinase may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational, Withdrawn
Valdecoxib	Valdecoxib may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational, Withdrawn
Valproic Acid	The serum concentration of Valproic Acid can be decreased when it is combined with Dabigatran etexilate.	Approved, Investigational
Velpatasvir	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Velpatasvir.	Approved, Investigational
Vemurafenib	The serum concentration of Dabigatran etexilate can be increased when it is combined with Vemurafenib.	Approved
Venlafaxine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Venlafaxine.	Approved
Verapamil	The serum concentration of Dabigatran etexilate can be increased when it is combined with Verapamil.	Approved
Vinblastine	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Vinblastine.	Approved
Vincristine	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Vincristine.	Approved, Investigational
Vinorelbine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Vinorelbine.	Approved, Investigational
Vitamin E	Vitamin E may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Nutraceutical, Vet Approved
Vorapaxar	The risk or severity of adverse effects can be increased when Vorapaxar is combined with Dabigatran etexilate.	Approved
Voxilaprevir	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Voxilaprevir.	Approved, Investigational
Warfarin	Dabigatran etexilate may increase the anticoagulant activities of Warfarin.	Approved
Ximelagatran	Dabigatran etexilate may increase the anticoagulant activities of Ximelagatran.	Approved, Investigational, Withdrawn
Zaltoprofen	Zaltoprofen may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational
Zeranol	Zeranol may decrease the anticoagulant activities of Dabigatran etexilate.	Vet Approved
Zidovudine	The serum concentration of Zidovudine can be decreased when it is combined with Dabigatran etexilate.	Approved
Zileuton	Zileuton may increase the anticoagulant activities of Dabigatran etexilate.	Approved, Investigational, Withdrawn
Zimelidine	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Zimelidine.	Withdrawn
Zomepirac	Zomepirac may increase the anticoagulant activities of Dabigatran etexilate.	Withdrawn

Food Interactions

St. John's Wort

References

Synthesis Reference

Christian Filser, Wolfgang Dersch, Rainer Hamm, Arndt Hausherr, Gunter Koch, Ulrich Scholz, Georg Zerban, "METHOD FOR PRODUCING AN INTERMEDIATE PRODUCT OF DABIGATRAN ETEXILATE." U.S. Patent US20110118471, issued May 19, 2011.

US20110118471

General References

Bauer KA: New oral anticoagulants in development: potential for improved safety profiles. Rev Neurol Dis. 2010;7(1):1-8. [PubMed:20410856]
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30. [PubMed:19717844]
Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI: Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost. 2009 Jan;101(1):77-85. [PubMed:19132192]
Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, Lieberman JR, Muntz JE, Raskob GE, Clements ML, Hantel S, Schnee JM, Caprini JA: Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009 Jan;24(1):1-9. doi: 10.1016/j.arth.2008.01.132. Epub 2008 Apr 14. [PubMed:18534438]
Eriksson BI, Dahl OE, Buller HR, Hettiarachchi R, Rosencher N, Bravo ML, Ahnfelt L, Piovella F, Stangier J, Kalebo P, Reilly P: A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. 2005 Jan;3(1):103-11. [PubMed:15634273]
Di Nisio M, Middeldorp S, Buller HR: Direct thrombin inhibitors. N Engl J Med. 2005 Sep 8;353(10):1028-40. [PubMed:16148288]
Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stahle H, Rathgen K, Svard R: Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005 May;45(5):555-63. [PubMed:15831779]
Ezekowitz MD, Reilly PA, Nehmiz G, Simmers TA, Nagarakanti R, Parcham-Azad K, Pedersen KE, Lionetti DA, Stangier J, Wallentin L: Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007 Nov 1;100(9):1419-26. Epub 2007 Aug 17. [PubMed:17950801]
Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kalebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Buller HR: Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007 Nov;5(11):2178-85. [PubMed:17764540]
Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Buller HR: Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007 Sep 15;370(9591):949-56. [PubMed:17869635]
Scaglione F: New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet. 2013 Feb;52(2):69-82. doi: 10.1007/s40262-012-0030-9. [PubMed:23292752]

External Links

Human Metabolome Database: HMDB0015641
KEGG Drug: D07144
PubChem Compound: 6445226
PubChem Substance: 99443249
ChemSpider: 4948999
BindingDB: 50432209
ChEBI: 70746
ChEMBL: CHEMBL539697
PharmGKB: PA165958369
RxList: RxList Drug Page
Drugs.com: Drugs.com Drug Page
PDRhealth: PDRhealth Drug Page
Wikipedia: Dabigatran

ATC Codes

B01AE07 — Dabigatran etexilate

AHFS Codes

20:12.04.12 — Direct Thrombin Inhibitors

FDA label

Download (431 KB)

MSDS

Download (99.2 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Active Not Recruiting	Treatment	Healthy Volunteers	2
1	Completed	Not Available	Cardiovascular Disease (CVD) / Kidney Failure,Chronic	1
1	Completed	Not Available	Healthy Volunteers	2
1	Completed	Basic Science	Disorders, Blood Coagulation	1
1	Completed	Basic Science	Healthy Volunteers	2
1	Completed	Other	Healthy Volunteers	1
1	Completed	Other	Prostatic Neoplasms	1
1	Completed	Treatment	Healthy Volunteers	28
1	Completed	Treatment	Hepatic Insufficiency	1
1	Completed	Treatment	Impaired Renal Function	1
1	Completed	Treatment	Non-Alcoholic Fatty Liver Disease (NAFLD)	1
1	Completed	Treatment	Renal Insufficiency,Chronic	1
1	Completed	Treatment	Thrombosis	1
1	Not Yet Recruiting	Other	Healthy Volunteers	1
1	Recruiting	Treatment	Interstitial Lung Disease (ILD) / Scleroderma	1
1	Terminated	Treatment	Healthy Volunteers	1
1	Unknown Status	Basic Science	Healthy Volunteers	1
2	Completed	Not Available	Venous Thromboembolism	2
2	Completed	Prevention	Arthroplasty, Replacement, Knee / Thrombosis, Venous	1
2	Completed	Prevention	Nonvalvular Atrial Fibrillation	1
2	Completed	Prevention	Venous Thromboembolism	1
2	Completed	Treatment	Coronary Heart Disease (CHD)	1
2	Completed	Treatment	Heart Catheterization	1
2	Completed	Treatment	Minor Ischemic Stroke / Transient Ischaemic Attack (TIA)	1
2	Completed	Treatment	Venous Thromboembolism	3
2	Recruiting	Treatment	Minor Ischemic Stroke / Transient Ischaemic Attack (TIA)	1
2	Terminated	Prevention	Heart Valve Diseases	1
2	Terminated	Prevention	Heart Valve Prosthesis / Thromboembolism	1
2	Terminated	Prevention	Nonvalvular Atrial Fibrillation / Strokes	1
2	Terminated	Treatment	Haemorrhage / Thrombosis	1
2	Unknown Status	Treatment	Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy	1
2	Withdrawn	Treatment	Venous Thromboembolism	1
2, 3	Terminated	Treatment	Primary Disease	1
3	Active Not Recruiting	Prevention	Secondary Preventions / Strokes	1
3	Active Not Recruiting	Treatment	Myocardial Injury After Noncardiac Surgery (MINS)	1
3	Active Not Recruiting	Treatment	Thromboembolism	1
3	Completed	Prevention	Arthroplasty, Replacement, Hip / Thromboembolism	1
3	Completed	Prevention	Arthroplasty, Replacement, Knee / Thromboembolism	2
3	Completed	Prevention	Venous Thromboembolism	1
3	Completed	Treatment	Nonvalvular Atrial Fibrillation / Percutaneous Coronary Intervention	1
3	Completed	Treatment	Thromboembolism	3
3	Not Yet Recruiting	Prevention	Atrial Flutter / Intracranial Hemorrhage, Hypertensive / Intracranial Hemorrhages / Intraventricular Hemorrhage / Microhaemorrhage / Nonvalvular Atrial Fibrillation / Small Vessel Cerebrovascular Disease / Subarachnoid Hemorrhage / Subdural haematoma	1
3	Not Yet Recruiting	Prevention	Nonvalvular Atrial Fibrillation / Thromboembolism	1
3	Not Yet Recruiting	Treatment	Nonvalvular Atrial Fibrillation	1
3	Recruiting	Prevention	Secondary Preventions / Venous Thromboembolism	1
3	Recruiting	Treatment	Cerebral Venous Thrombosis	1
3	Recruiting	Treatment	Deep Vein Thrombosis (DVT) / Pulmonary Embolism (PE) / Venous Thromboembolism	1
3	Recruiting	Treatment	Hematoma	1
3	Recruiting	Treatment	Venous Thromboembolism	1
3	Unknown Status	Prevention	Venous Thromboembolism	1
4	Active Not Recruiting	Supportive Care	Atrial Flutter / Nonvalvular Atrial Fibrillation	1
4	Completed	Basic Science	Venous Thromboembolism	1
4	Completed	Prevention	Arthroplasty, Replacement / Moderate Renal Impairment (CrCl 30-50 mL/Min) / Prevention of Venous Thromboembolism	1
4	Completed	Prevention	Nonvalvular Atrial Fibrillation	2
4	Completed	Treatment	Coronary Heart Disease (CHD)	1
4	Completed	Treatment	Nonvalvular Atrial Fibrillation	4
4	Enrolling by Invitation	Treatment	Nonvalvular Atrial Fibrillation	1
4	Recruiting	Other	Cerebral Ischemic Events / Cognition Disorders / Dementias	1
4	Recruiting	Prevention	Nonvalvular Atrial Fibrillation	3
4	Recruiting	Treatment	(Atrial Fibrillation) or (Atrial Flutter) / Thrombosis of Left Atrial Appendage	1
4	Recruiting	Treatment	Angiographically Confirmed Acute Massive Pulmonary Embolism Treated With Endovascular Mechanical Fragmentation and Thrombolytic Therapy / Dabigatran Etexilate / Pulmonary Embolism (PE) / Recurrence of DVT / Warfarin	1
4	Recruiting	Treatment	Cardioembolic Events / Nonvalvular Atrial Fibrillation / Oral Anticoagulation	1
4	Recruiting	Treatment	Deep Vein Thrombosis (DVT) / Pulmonary Embolism (PE)	1
4	Recruiting	Treatment	Diabetes Mellitus (DM)	1
4	Recruiting	Treatment	Left Atrial Thrombosis / Nonvalvular Atrial Fibrillation	1
4	Recruiting	Treatment	Nonvalvular Atrial Fibrillation	2
4	Recruiting	Treatment	Nonvalvular Atrial Fibrillation / Valve Heart Disease	1
4	Recruiting	Treatment	Pulmonary Embolism (PE)	1
4	Terminated	Diagnostic	Nonvalvular Atrial Fibrillation	1
4	Terminated	Treatment	Acute Coronary Syndromes (ACS) / Atherosclerosis / Coronary Heart Disease (CHD) / Nonvalvular Atrial Fibrillation	1
4	Unknown Status	Not Available	Anticoagulant Overdosage / Anticoagulant-induced Bleeding / Hemorrhage / Thrombosis	1
4	Withdrawn	Treatment	Coronary Heart Disease (CHD) / Non ST Segment Elevation Myocardial Infarction (NSTEMI) / ST Elevation Myocardial Infarction (STEMI) / Stable Angina (SA) / Unstable Angina (UA)	1
4	Withdrawn	Treatment	Thromboembolism	1
Not Available	Active Not Recruiting	Not Available	Anticoagulation	1
Not Available	Active Not Recruiting	Not Available	Nonvalvular Atrial Fibrillation	1
Not Available	Completed	Not Available	Hemorrhage / Nonvalvular Atrial Fibrillation	1
Not Available	Completed	Not Available	Major Bleeding / Venous Thromboembolism	1
Not Available	Completed	Not Available	Nonvalvular Atrial Fibrillation	11
Not Available	Completed	Not Available	Nonvalvular Atrial Fibrillation / Strokes Thrombotic	1
Not Available	Completed	Not Available	Strokes	1
Not Available	Completed	Treatment	Coronary Artery Disease	1
Not Available	Completed	Treatment	Nonvalvular Atrial Fibrillation	1
Not Available	Enrolling by Invitation	Treatment	Acute DVT of Lower Extremity	1
Not Available	Not Yet Recruiting	Not Available	Nonvalvular Atrial Fibrillation	2
Not Available	Not Yet Recruiting	Basic Science	Idiopathic Pulmonary Fibrosis (IPF) / Interstitial Lung Disease (ILD) / IPF	1
Not Available	Recruiting	Not Available	Anticoagulants / Nonvalvular Atrial Fibrillation / Pharmacoepidemiology	1
Not Available	Recruiting	Not Available	Cardioembolic Stroke	1
Not Available	Recruiting	Not Available	Ischemic Attack, Transient / Strokes	1
Not Available	Recruiting	Not Available	Nonvalvular Atrial Fibrillation	2
Not Available	Recruiting	Not Available	Unsuspected Pulmonary Embolism	1
Not Available	Recruiting	Supportive Care	Hemorrhage / Nonvalvular Atrial Fibrillation / Periodontal Diseases	1
Not Available	Recruiting	Treatment	Anticoagulant Adverse Reaction / Hemorrhage / Nonvalvular Atrial Fibrillation / Thrombosis	1
Not Available	Recruiting	Treatment	Blood Clots / Cancers / Deep Vein Thrombosis (DVT) / Pulmonary Embolism (PE) / Venous Thromboembolism	1
Not Available	Terminated	Not Available	Arthroplasty, Replacement / Venous Thromboembolism	1
Not Available	Unknown Status	Supportive Care	Blood Loss / Osteoarthritis, Hip	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage forms

Form	Route	Strength
Capsule	Oral	110 mg
Capsule	Oral	110 mg/1
Capsule	Oral	150 mg/1
Capsule	Oral	150 mg
Capsule	Oral	75 mg
Capsule	Oral	75 mg/1

Prices

Not Available

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US9034822	No	2011-01-20	2031-01-20
US6087380	No	1998-02-18	2018-02-18
US7932273	No	2005-09-07	2025-09-07
US7866474	No	2007-08-31	2027-08-31

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	180 +/- 3 (DSC: 10 K min^-1 heating rate)	Not Available
water solubility	1.8mg/ml, partly soluble	MSDS
logP	3.8	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.00466 mg/mL	ALOGPS
logP	5.17	ALOGPS
logP	4.59	ChemAxon
logS	-5.1	ALOGPS
pKa (Strongest Acidic)	17.89	ChemAxon
pKa (Strongest Basic)	3.87	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	8	ChemAxon
Hydrogen Donor Count	2	ChemAxon
Polar Surface Area	154.03 Å²	ChemAxon
Rotatable Bond Count	17	ChemAxon
Refractivity	176.43 m³·mol^-1	ChemAxon
Polarizability	71.11 Å³	ChemAxon
Number of Rings	4	ChemAxon
Bioavailability	0	ChemAxon
Rule of Five	No	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.942
Blood Brain Barrier	+	0.8673
Caco-2 permeable	-	0.7014
P-glycoprotein substrate	Substrate	0.7412
P-glycoprotein inhibitor I	Inhibitor	0.7539
P-glycoprotein inhibitor II	Inhibitor	0.8443
Renal organic cation transporter	Non-inhibitor	0.701
CYP450 2C9 substrate	Non-substrate	0.858
CYP450 2D6 substrate	Non-substrate	0.837
CYP450 3A4 substrate	Substrate	0.6154
CYP450 1A2 substrate	Non-inhibitor	0.6906
CYP450 2C9 inhibitor	Non-inhibitor	0.5102
CYP450 2D6 inhibitor	Non-inhibitor	0.8417
CYP450 2C19 inhibitor	Inhibitor	0.5157
CYP450 3A4 inhibitor	Inhibitor	0.781
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.5789
Ames test	Non AMES toxic	0.6292
Carcinogenicity	Non-carcinogens	0.8065
Biodegradation	Not ready biodegradable	0.9931
Rat acute toxicity	2.7093 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9047
hERG inhibition (predictor II)	Inhibitor	0.6181

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	Not Available
MS/MS Spectrum - , positive	LC-MS/MS	splash10-00kk-0981100000-78856b63936cf67ebce2
MS/MS Spectrum - , positive	LC-MS/MS	splash10-004r-0292116000-55b368cbe92da888e681

Taxonomy

Description: This compound belongs to the class of organic compounds known as benzimidazoles. These are organic compounds containing a benzene ring fused to an imidazole ring (five member ring containing a nitrogen atom, 4 carbon atoms, and two double bonds).
Kingdom: Organic compounds
Super Class: Organoheterocyclic compounds
Class: Benzimidazoles
Sub Class: Not Available
Direct Parent: Benzimidazoles
Alternative Parents: Phenylalkylamines / Aniline and substituted anilines / Secondary alkylarylamines / Pyridines and derivatives / N-substituted imidazoles / Imidolactams / Tertiary carboxylic acid amides / Heteroaromatic compounds / Amino acids and derivatives / Carboxylic acid esters
show 10 more
Substituents: Benzimidazole / Aniline or substituted anilines / Phenylalkylamine / Secondary aliphatic/aromatic amine / Aralkylamine / Monocyclic benzene moiety / N-substituted imidazole / Pyridine / Benzenoid / Imidolactam
show 27 more
Molecular Framework: Aromatic heteropolycyclic compounds
External Descriptors: carboxylic ester, carboxamidine, beta-alanine derivative, pyridines, aromatic amide, benzimidazoles (CHEBI:70746)

Targets

Details1. Prothrombin

Kind: Protein
Organism: Human
Pharmacological action: Yes
Actions: Inhibitor

General Function: Thrombospondin receptor activity
Specific Function: Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostas...
Gene Name: F2
Uniprot ID: P00734
Uniprot Name: Prothrombin
Molecular Weight: 70036.295 Da

References

Squizzato A, Dentali F, Steidl L, Ageno W: New direct thrombin inhibitors. Intern Emerg Med. 2009 Dec;4(6):479-84. doi: 10.1007/s11739-009-0314-8. Epub 2009 Sep 15. [PubMed:19756950]
Liesenfeld KH, Schafer HG, Troconiz IF, Tillmann C, Eriksson BI, Stangier J: Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol. 2006 Nov;62(5):527-37. [PubMed:17061960]
Karthikeyan G, Eikelboom JW, Hirsh J: Dabigatran: ready for prime time? Pol Arch Med Wewn. 2010 Apr;120(4):137-42. [PubMed:20424539]

Enzymes

Details1. Liver carboxylesterase 1

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Triglyceride lipase activity
Specific Function: Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acy...
Gene Name: CES1
Uniprot ID: P23141
Uniprot Name: Liver carboxylesterase 1
Molecular Weight: 62520.62 Da

References

Hu ZY, Parker RB, Herring VL, Laizure SC: Conventional liquid chromatography/triple quadrupole mass spectrometry based metabolite identification and semi-quantitative estimation approach in the investigation of in vitro dabigatran etexilate metabolism. Anal Bioanal Chem. 2013 Feb;405(5):1695-704. doi: 10.1007/s00216-012-6576-4. Epub 2012 Dec 14. [PubMed:23239178]

Details2. Cocaine esterase

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Methylumbelliferyl-acetate deacetylase activity
Specific Function: Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Shows high catalytic efficiency for hydrolysis of cocaine, 4-methylumbelliferyl acetate, heroin and ...
Gene Name: CES2
Uniprot ID: O00748
Uniprot Name: Cocaine esterase
Molecular Weight: 61806.41 Da

References

Hu ZY, Parker RB, Herring VL, Laizure SC: Conventional liquid chromatography/triple quadrupole mass spectrometry based metabolite identification and semi-quantitative estimation approach in the investigation of in vitro dabigatran etexilate metabolism. Anal Bioanal Chem. 2013 Feb;405(5):1695-704. doi: 10.1007/s00216-012-6576-4. Epub 2012 Dec 14. [PubMed:23239178]

Details3. UDP-glucuronosyltransferase 1-9

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Retinoic acid binding
Specific Function: UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks trans...
Gene Name: UGT1A9
Uniprot ID: O60656
Uniprot Name: UDP-glucuronosyltransferase 1-9
Molecular Weight: 59940.495 Da

References

Ebner T, Wagner K, Wienen W: Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos. 2010 Sep;38(9):1567-75. doi: 10.1124/dmd.110.033696. Epub 2010 Jun 15. [PubMed:20551237]

Details4. UDP-glucuronosyltransferase 2B7

Kind: Protein
Organism: Human
Pharmacological action: Unknown

General Function: Glucuronosyltransferase activity
Specific Function: UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
Gene Name: UGT2B7
Uniprot ID: P16662
Uniprot Name: UDP-glucuronosyltransferase 2B7
Molecular Weight: 60694.12 Da

References

Ebner T, Wagner K, Wienen W: Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos. 2010 Sep;38(9):1567-75. doi: 10.1124/dmd.110.033696. Epub 2010 Jun 15. [PubMed:20551237]

Details5. UDP-glucuronosyltransferase 2B15

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Glucuronosyltransferase activity
Specific Function: UDPGTs are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isozyme displays activity toward several classes of xeno...
Gene Name: UGT2B15
Uniprot ID: P54855
Uniprot Name: UDP-glucuronosyltransferase 2B15
Molecular Weight: 61035.815 Da

References

Ebner T, Wagner K, Wienen W: Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos. 2010 Sep;38(9):1567-75. doi: 10.1124/dmd.110.033696. Epub 2010 Jun 15. [PubMed:20551237]

Details6. Ribosyldihydronicotinamide dehydrogenase [quinone]

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Nadph dehydrogenase (quinone) activity
Specific Function: The enzyme apparently serves as a quinone reductase in connection with conjugation reactions of hydroquinones involved in detoxification pathways as well as in biosynthetic processes such as the vi...
Gene Name: NQO2
Uniprot ID: P16083
Uniprot Name: Ribosyldihydronicotinamide dehydrogenase [quinone]
Molecular Weight: 25918.4 Da

References

Michaelis S, Marais A, Schrey AK, Graebner OY, Schaudt C, Sefkow M, Kroll F, Dreger M, Glinski M, Koester H, Metternich R, Fischer JJ: Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2). J Med Chem. 2012 Apr 26;55(8):3934-44. doi: 10.1021/jm3001339. Epub 2012 Apr 17. [PubMed:22494098]

Transporters

Details1. Multidrug resistance protein 1

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Xenobiotic-transporting atpase activity
Specific Function: Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name: ABCB1
Uniprot ID: P08183
Uniprot Name: Multidrug resistance protein 1
Molecular Weight: 141477.255 Da

References

Galanis T, Thomson L, Palladino M, Merli GJ: New oral anticoagulants. J Thromb Thrombolysis. 2011 Apr;31(3):310-20. doi: 10.1007/s11239-011-0559-8. [PubMed:21327511]
Scaglione F: New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet. 2013 Feb;52(2):69-82. doi: 10.1007/s40262-012-0030-9. [PubMed:23292752]

Drug created on May 03, 2010 12:25 / Updated on April 23, 2018 23:11

Dabigatran etexilate

Identification

Structure for DB06695 (Dabigatran etexilate)

Pharmacology

Interactions

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Taxonomy

Targets

References

Enzymes

References

References

References

References

References

References

Transporters

References